Bayer Aktiengesellschaft / Key word(s): Research Update

29.09.2011 23:15

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

Bayer Aktiengesellschaft: Phase III Study of Bayer's Rivaroxaban in
Patients with Acute Coronary Syndrome Meets Primary Efficacy Endpoint

Leverkusen, Germany, September 29, 2011 - Bayer AG announced today that the
double blind, placebo controlled Phase III ATLAS ACS TIMI 51 clinical trial
of Rivaroxaban plus standard therapy has met its primary efficacy endpoint,
showing a statistically significant reduction in the rate of events for the
primary composite endpoint of cardiovascular death, myocardial infarction
and stroke in patients with ACS, compared to standard therapy plus placebo.
For the primary safety endpoint, defined as major bleeding events not
associated with Coronary Artery Bypass Graft surgery according to the
TIMI-classification, there was a statistically significant increase in such
events in patients receiving Rivaroxaban versus placebo.

It is intended to present these data as soon as possible at a forthcoming
scientific congress as well as to file for market authorization by the end
of this year.

Information and Explaination of the Issuer to this News:

Forward-Looking Statements
This Ad-hoc Statement may contain forward-looking statements based on
current assumptions and forecasts made by Bayer Group or subgroup
management. Various known and unknown risks, uncertainties and other
factors could lead to material differences between the actual future
results, financial situation, development or performance of the company and
the estimates given here. These factors include those discussed in Bayer's
public reports, which are available on the Bayer website at www.bayer.com.
The company assumes no liability whatsoever to update these forward-looking
statements or to conform them to future events or developments.

29.09.2011 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

Language: English
Company: Bayer Aktiengesellschaft
Kaiser-Wilhelm-Allee 1
51373 Leverkusen
Germany
Phone: +49 (0)21430-1
Fax: +49 (0)21430-66328
E-mail: alexander.rosar.ar1@bayer-ag.de
Internet: www.bayer-ag.de
ISIN: DE000BAY0017
WKN: BAY001
Indices: DAX, EURO STOXX 50, Stoxx 50
Listed: Regulierter Markt in Berlin, Düsseldorf, Frankfurt (Prime
Standard), Hamburg, Hannover, München, Stuttgart; Terminbörse
EUREX; London, Madrid, SIX

End of Announcement DGAP News-Service


(END) Dow Jones Newswires

September 29, 2011 17:15 ET (21:15 GMT)